Polarity changes in the transmembrane domain core of HIV-1 vpu inhibits its anti-tetherin activity

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Lv, Mingyu ^a   Wang, Jiawen ^a   Wang, Xiaodan ^a   Zuo, Tao ^a   Zhu, Yingzi ^a   Kong, Wei ^a   Yu, Xianghui ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; ISOLEUCINE; TETHERIN; UNCLASSIFIED DRUG; VPU PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BST2 PROTEIN, HUMAN; CD4 ANTIGEN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LEUKOCYTE ANTIGEN; VIRUS PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; GENE DELETION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; MUTATIONAL ANALYSIS; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; VIRUS PARTICLE; VIRUS RELEASE; WILD TYPE; CELL MEMBRANE; CELL STRAIN HEK293; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECT; FEASIBILITY STUDY; GENETICS; HELA CELL; METABOLISM; MOLECULAR GENETICS; MUTAGENESIS; MUTATION; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIGENS, CD; ANTIGENS, CD4; CELL MEMBRANE; DOWN-REGULATION; FEASIBILITY STUDIES; GPI-LINKED PROTEINS; HEK293 CELLS; HELA CELLS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MOLECULAR SEQUENCE DATA; MUTAGENESIS; MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS RELEASE;

EID: 79957966644     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020890     Document Type: Article

References (67)

1. Goff SP, (2007) Host factors exploited by retroviruses. Nat Rev Microbiol 5: 253-263.
2. Sheehy AM, Gaddis NC, Choi JD, Malim MH, (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
3. Stremlau M, Perron M, Lee M, Li Y, Song B, et al. (2006) Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A 103: 5514-5519.
4. Neil SJ, Zang T, Bieniasz PD, (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425-430.
5. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, et al. (2008) The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3: 245-252.
6. Yu X, Yu Y, Liu B, Luo K, Kong W, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: 1056-1060.
7. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, et al. (2003) Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4: 694-709.
8. Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, et al. (2009) Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 83: 1837-1844.
9. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J, (2009) Inhibition of Lassa and Marburg virus production by tetherin. J Virol 83: 2382-2385.
10. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P, (2009) Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A 106: 2886-2891.
11. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, et al. (2009) Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139: 499-511.
12. Cohen EA, Terwilliger EF, Sodroski JG, Haseltine WA, (1988) Identification of a protein encoded by the vpu gene of HIV-1. Nature 334: 532-534.
13. Strebel K, Klimkait T, Martin MA, (1988) A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 241: 1221-1223.
14. Maldarelli F, Chen MY, Willey RL, Strebel K, (1993) Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J Virol 67: 5056-5061.
15. Subbramanian RA, Cohen EA, (1994) Molecular biology of the human immunodeficiency virus accessory proteins. J Virol 68: 6831-6835.
16. Schubert U, Bour S, Ferrer-Montiel AV, Montal M, Maldarell F, et al. (1996) The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol 70: 809-819.
17. Schubert U, Schneider T, Henklein P, Hoffmann K, Berthold E, et al. (1992) Human-immunodeficiency-virus-type-1-encoded Vpu protein is phosphorylated by casein kinase II. Eur J Biochem 204: 875-883.
18. Paul M, Mazumder S, Raja N, Jabbar MA, (1998) Mutational analysis of the human immunodeficiency virus type 1 Vpu transmembrane domain that promotes the enhanced release of virus-like particles from the plasma membrane of mammalian cells. J Virol 72: 1270-1279.
19. Iwabu Y, Fujita H, Kinomoto M, Kaneko K, Ishizaka Y, et al. (2009) HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem 284: 35060-35072.
20. Banning C, Votteler J, Hoffmann D, Koppensteiner H, Warmer M, et al. (2010) A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells. PLoS One 5: e9344.
21. Grantham R, (1974) Amino acid difference formula to help explain protein evolution. Science 185: 862-864.
22. Varthakavi V, Smith RM, Martin KL, Derdowski A, Lapierre LA, et al. (2006) The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic 7: 298-307.
23. Pacyniak E, Gomez ML, Gomez LM, Mulcahy ER, Jackson M, et al. (2005) Identification of a region within the cytoplasmic domain of the subtype B Vpu protein of human immunodeficiency virus type 1 (HIV-1) that is responsible for retention in the golgi complex and its absence in the Vpu protein from a subtype C HIV-1. AIDS Res Hum Retroviruses 21: 379-394.
24. Dube M, Roy BB, Guiot-Guillain P, Mercier J, Binette J, et al. (2009) Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol 83: 4574-4590.
25. Terwilliger EF, Cohen EA, Lu YC, Sodroski JG, Haseltine WA, (1989) Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci U S A 86: 5163-5167.
26. Gottlinger HG, Dorfman T, Cohen EA, Haseltine WA, (1993) Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci U S A 90: 7381-7385.
27. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, et al. (2009) HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 5: e1000574.
28. Willey RL, Maldarelli F, Martin MA, Strebel K, (1992) Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 66: 7193-7200.
29. Bour S, Schubert U, Strebel K, (1995) The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J Virol 69: 1510-1520.
30. Margottin F, Benichou S, Durand H, Richard V, Liu LX, et al. (1996) Interaction between the cytoplasmic domains of HIV-1 Vpu and CD4: role of Vpu residues involved in CD4 interaction and in vitro CD4 degradation. Virology 223: 381-386.
31. Tiganos E, Friborg J, Allain B, Daniel NG, Yao XJ, et al. (1998) Structural and functional analysis of the membrane-spanning domain of the human immunodeficiency virus type 1 Vpu protein. Virology 251: 96-107.
32. Ewart GD, Sutherland T, Gage PW, Cox GB, (1996) The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J Virol 70: 7108-7115.
33. Schubert U, Ferrer-Montiel AV, Oblatt-Montal M, Henklein P, Strebel K, et al. (1996) Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett 398: 12-18.
34. Varthakavi V, Smith RM, Bour SP, Strebel K, Spearman P, (2003) Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci U S A 100: 15154-15159.
35. Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G, (2007) Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci 120: 3850-3858.
36. Skasko M, Tokarev A, Chen CC, Fischer WB, Pillai SK, et al. (2011) BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action. Virology 411: 65-77.
37. Gupta RK, Hue S, Schaller T, Verschoor E, Pillay D, et al. (2009) Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog 5: e1000443.
38. Douglas JL, Viswanathan K, McCarroll MN, Gustin JK, Fruh K, et al. (2009) Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J Virol 83: 7931-7947.
39. Goffinet C, Allespach I, Homann S, Tervo HM, Habermann A, et al. (2009) HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5: 285-297.
40. Miyagi E, Andrew AJ, Kao S, Strebel K, (2009) Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A 106: 2868-2873.
41. Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, et al. (2009) Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog 5: e1000450.
42. Goffinet C, Homann S, Ambiel I, Tibroni N, Rupp D, et al. (2010) Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J Virol 84: 4089-4094.
43. Andrew AJ, Miyagi E, Strebel K, (2011) Differential Effects of Human Immunodeficiency Virus Type 1 Vpu on the Stability of BST-2/Tetherin. J Virol 85: 2611-2619.
44. Douglas JL, Gustin JK, Viswanathan K, Mansouri M, Moses AV, et al. (2010) The great escape: viral strategies to counter BST-2/tetherin. PLoS Pathog 6: e1000913.
45. Tokarev AA, Munguia J, Guatelli JC, (2011) Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J Virol 85: 51-63.
46. Tervo HM, Homann S, Ambiel I, Fritz JV, Fackler OT, et al. (2011) beta-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release. Retrovirology 8: 9.
47. Margottin F, Bour SP, Durand H, Selig L, Benichou S, et al. (1998) A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1: 565-574.
48. Magadan JG, Perez-Victoria FJ, Sougrat R, Ye Y, Strebel K, et al. (2010) Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog 6: e1000869.
49. Vigan R, Neil SJ, (2010) Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol 84: 12958-12970.
50. Ruiz A, Hill MS, Schmitt K, Stephens EB, (2010) Membrane raft association of the Vpu protein of human immunodeficiency virus type 1 correlates with enhanced virus release. Virology 408: 89-102.
51. Becker CF, Oblatt-Montal M, Kochendoerfer GG, Montal M, (2004) Chemical synthesis and single channel properties of tetrameric and pentameric TASPs (template-assembled synthetic proteins) derived from the transmembrane domain of HIV virus protein u (Vpu). J Biol Chem 279: 17483-17489.
52. Kochendoerfer GG, Jones DH, Lee S, Oblatt-Montal M, Opella SJ, et al. (2004) Functional characterization and NMR spectroscopy on full-length Vpu from HIV-1 prepared by total chemical synthesis. J Am Chem Soc 126: 2439-2446.
53. Park SH, Mrse AA, Nevzorov AA, Mesleh MF, Oblatt-Montal M, et al. (2003) Three-dimensional structure of the channel-forming trans-membrane domain of virus protein "u" (Vpu) from HIV-1. J Mol Biol 333: 409-424.
54. Ma C, Marassi FM, Jones DH, Straus SK, Bour S, et al. (2002) Expression, purification, and activities of full-length and truncated versions of the integral membrane protein Vpu from HIV-1. Protein Sci 11: 546-557.
55. Lemaitre V, Willbold D, Watts A, Fischer WB, (2006) Full length Vpu from HIV-1: combining molecular dynamics simulations with NMR spectroscopy. J Biomol Struct Dyn 23: 485-496.
56. Montal M, (2003) Structure-function correlates of Vpu, a membrane protein of HIV-1. FEBS Lett 552: 47-53.
57. Marassi FM, Ma C, Gratkowski H, Straus SK, Strebel K, et al. (1999) Correlation of the structural and functional domains in the membrane protein Vpu from HIV-1. Proc Natl Acad Sci U S A 96: 14336-14341.
58. Fischer WB, (2003) Vpu from HIV-1 on an atomic scale: experiments and computer simulations. FEBS Lett 552: 39-46.
59. Mehnert T, Lam YH, Judge PJ, Routh A, Fischer D, et al. (2007) Towards a mechanism of function of the viral ion channel Vpu from HIV-1. J Biomol Struct Dyn 24: 589-596.
60. Kruger J, Fischer WB, (2010) Structural implications of mutations assessed by molecular dynamics: Vpu1-32 from HIV-1. Eur Biophys J 39: 1069-1077.
61. Patargias G, Martay H, Fischer WB, (2009) Reconstructing potentials of mean force from short steered molecular dynamics simulations of Vpu from HIV-1. J Biomol Struct Dyn 27: 1-12.
62. Lemaitre V, Ali R, Kim CG, Watts A, Fischer WB, (2004) Interaction of amiloride and one of its derivatives with Vpu from HIV-1: a molecular dynamics simulation. FEBS Lett 563: 75-81.
63. Waheed AA, Ablan SD, Soheilian F, Nagashima K, Ono A, et al. (2008) Inhibition of human immunodeficiency virus type 1 assembly and release by the cholesterol-binding compound amphotericin B methyl ester: evidence for Vpu dependence. J Virol 82: 9776-9781.
64. Montal M, (2009) Vpu matchmakers as a therapeutic strategy for HIV infection. PLoS Pathog 5: e1000246.
65. Fischer WB, Kruger J, (2009) Viral channel-forming proteins. Int Rev Cell Mol Biol 275: 35-63.
66. Nguyen KL, llano M, Akari H, Miyagi E, Poeschla EM, et al. (2004) Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 319: 163-175.
67. Neil SJ, Eastman SW, Jouvenet N, Bieniasz PD, (2006) HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog 2: e39.